RxDoctor Payments Data

Ruben Tenorio, DO

Internal Medicine · San Antonio, TXNPI 1134255250

Payments from drug & device makers

$4,678in general payments, 2019–2025

Across 53 payments — averaging $88.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$4K
  • Astellas Pharma US Inc$217
  • Lilly USA, LLC$192
  • Novo Nordisk$148
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$110
  • AstraZeneca$83
  • plus $335 from 8 others

What the payments were for

  • Consulting fees$3758%
  • Speaking & faculty fees$3,15067%
  • Food & beverage$96721%
  • Education$1854%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,678 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$24,143
Medicare patients
57
Services billed
585

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide291$320,453
FarxigaDapagliflozin Propanediol121$116,292
JardianceEmpagliflozin90$91,810
OzempicSemaglutide40$52,443
EliquisApixaban60$45,627
AfrezzaInsulin Regular, Human14$32,780
KerendiaFinerenone23$28,364
MyrbetriqMirabegron36$23,956
JanuviaSitagliptin Phosphate20$21,012
LinzessLinaclotide24$19,636
Repatha SureclickEvolocumab32$18,388
DapagliflozinDapagliflozin Propanediol23$14,987
Tresiba Flextouch U-200Insulin Degludec15$14,672
XareltoRivaroxaban17$13,542
TradjentaLinagliptin17$13,120

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$192$320,453291 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$83$127,547150 claims
Boehringer IngelheimJardiance, Tradjenta, Trijardy Xr$35$112,056119 claims
Novo NordiskOzempic$148$52,44340 claims
BayerKerendia$68$28,36423 claims
Johnson & JohnsonXarelto, Invokana$3,593$25,71336 claims
Astellas Pharma US IncMyrbetriq$217$23,95636 claims
MerckJanuvia$24$21,01220 claims
AbbVieLinzess$14$19,63624 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →